肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：干扰素γ信使RNA特征可以预测患者结局

2018-08-28 MedSci MedSci原创

非小细胞肺癌尿路上皮癌信使RNA干扰素γ
关注

durvalumab是一种抗PD-L1单克隆抗体。CLIN CANCER RES近期发表了一篇文章， 研究durvalumab的预测性生物学标志。

durvalumab是一种抗PD-L1单克隆抗体。CLIN CANCER RES近期发表了一篇文章， 研究durvalumab的预测性生物学标志。

作者对一项非随机临床试验中的97例晚期非小细胞肺癌活检标本进行RNA测序以寻找预测下标志。来自同一临床试验的局部晚期或转移性尿路上皮癌患者62例用于验证该特征的预测价值。30例非小细胞肺癌患者提供了治疗前及治疗后肿瘤标本进行信使RNA分析。使用K-M曲线及Cox模型调整性别，年龄，治疗史，组织学，ECOG状态，肝转移和吸烟史等影响。使用TCGA数据库数据计算肿瘤突变负荷（TMB）。研究结果表明，在非小细胞肺癌发现队列，一种4个基因的IFNγ阳性特征与更高的总缓解率，更长的无进展生存期及总生存期有关。IFNγ阳性特征的非小细胞肺癌患者预后改善，且与PD-L1状态无关。在尿路上皮癌队列中这些相关性得到验证。非小细胞肺癌患者接受durvalumab治疗8周后IFNγ阳性特征被诱导增加两倍，TCGA数据研究表明基线时该特征与肿瘤突变负荷有关，但与生存无关。

文章最后认为，IFNγ+ mRNA特征可能有助于识别接受durvalumab治疗有预后改善的患者。

原始出处：

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1480014, encodeId=70db148001485, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Thu Aug 30 11:28:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341743, encodeId=7d4b341e4311, content=嗯嗯，学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Aug 30 08:14:47 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341579, encodeId=ac083415e97e, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Aug 29 07:56:22 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341517, encodeId=e7f934151e44, content=了解一下，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Aug 28 21:05:05 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341508, encodeId=cf94341508e9, content=学习了，谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Aug 28 21:02:04 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
    2018-08-30 ms5906905816781247

    #患者结局#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1480014, encodeId=70db148001485, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Thu Aug 30 11:28:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341743, encodeId=7d4b341e4311, content=嗯嗯，学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Aug 30 08:14:47 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341579, encodeId=ac083415e97e, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Aug 29 07:56:22 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341517, encodeId=e7f934151e44, content=了解一下，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Aug 28 21:05:05 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341508, encodeId=cf94341508e9, content=学习了，谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Aug 28 21:02:04 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
    2018-08-30 liumin1987

    嗯嗯，学习了。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1480014, encodeId=70db148001485, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Thu Aug 30 11:28:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341743, encodeId=7d4b341e4311, content=嗯嗯，学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Aug 30 08:14:47 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341579, encodeId=ac083415e97e, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Aug 29 07:56:22 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341517, encodeId=e7f934151e44, content=了解一下，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Aug 28 21:05:05 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341508, encodeId=cf94341508e9, content=学习了，谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Aug 28 21:02:04 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
    2018-08-29 kafei

    学习了谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1480014, encodeId=70db148001485, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Thu Aug 30 11:28:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341743, encodeId=7d4b341e4311, content=嗯嗯，学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Aug 30 08:14:47 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341579, encodeId=ac083415e97e, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Aug 29 07:56:22 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341517, encodeId=e7f934151e44, content=了解一下，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Aug 28 21:05:05 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341508, encodeId=cf94341508e9, content=学习了，谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Aug 28 21:02:04 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
    2018-08-28 天地飞扬

    了解一下，谢谢分享！

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1480014, encodeId=70db148001485, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Thu Aug 30 11:28:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341743, encodeId=7d4b341e4311, content=嗯嗯，学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Aug 30 08:14:47 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341579, encodeId=ac083415e97e, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Aug 29 07:56:22 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341517, encodeId=e7f934151e44, content=了解一下，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Aug 28 21:05:05 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341508, encodeId=cf94341508e9, content=学习了，谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Aug 28 21:02:04 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
    2018-08-28 惠映实验室

    学习了，谢谢分享。

    0

相关资讯

Autophagy：楝酰胺抑制自噬，增强NK细胞杀伤非小细胞肺癌

在最近的一项研究中，来自上海中医药大学的研究人员发现天然产物楝酰胺（RocA）增强了自然杀伤（NK）细胞介导的体外非小细胞肺癌（NSCLC）细胞的裂解，以及体内肿瘤消退。

Radiology：非小细胞肺癌治疗新方法！

本研究旨在验证肿瘤内射频热疗（RFH）增强单纯疱疹病毒（HSV）胸苷激酶(TK)联合更昔洛韦（GCV）基因疗法治疗非小细胞肺癌（NSCLC）的可行性及效果，将结果发表在Radiology上。

JCO：基线类固醇对非小细胞肺癌患者PD-1/PD-L1阻断治疗有效性的影响

PD-1或PD-L1抑制剂目前是肺癌患者的标准治疗方案。皮质类固醇激素的免疫抑制作用可能会降低PD-（L）1的有效性。皮质类固醇激素治疗免疫相关不良反应时看起来不会影响有效性，但是治疗开始时基线皮质类固醇激素的潜在影响尚不清楚。JCO近期发表了一篇文章，研究治疗开始时皮质类固醇激素的作用。

JAMA：测那么多基因也没用？耶鲁科学家发现，广谱基因检测不能提高晚期非小细胞肺癌患者生存率

癌细胞大多不止存在一个基因突变，那么同时检测多个基因，也就是我们说的广谱基因检测（BGS），行内人常说的“大panel”，是不是应该给患者带来更好的健康收益呢？

Thorax：非小细胞肺癌患者年龄、贫困和特定合并症与接受大手术的关联

合并症在患者是否接受手术方面发挥着重要作用，但不能完全解释在早期患者中观察到的社会经济差距。

NCCN临床实践指南：非小细胞肺癌（2018.V6）

2018年8月，美国国家综合癌症网络(NCCN)发布了非小细胞肺癌指南2018年第6版，指南较2018年第5版更新内容有：鳞状细胞癌的治疗：派姆单抗/卡铂/白蛋白结合紫杉醇加入一线治疗选择.推荐等级2A；讨论部分更新。